References
- O’Callaghan FJ, Shiell AW, Osborne JP, et al. Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet. [cited 2019 Feb 28]. 1998;351:1490. http://www.ncbi.nlm.nih.gov/pubmed/9605811
- Aronica E, Specchio N, Luinenburg MJ, et al. Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy. [cited 2023 May 14]; DOI:10.1093/brain/awad048
- Northrup H, Krueger DA, Northrup H, et al. Tuberous Sclerosis Complex Diagnostic Criteria Update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol [Internet]. 2013 [cited 2019 Feb 28];49:243–254. http://www.ncbi.nlm.nih.gov/pubmed/24053982
- Northrup H, ME A, EM B, et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol [Internet]. 2021 [cited 2023 Apr 27];123:50–66. https://pubmed.ncbi.nlm.nih.gov/34399110/
- Kingswood JC, d’Augères GB, Belousova E, et al. TuberOus SClerosis registry to increase disease Awareness (TOSCA) – baseline data on 2093 patients. Orphanet J Rare Dis. [cited 2019 Feb 28]. 2017;12:2. http://www.ncbi.nlm.nih.gov/pubmed/28057044
- Lux AL, Osborne JP. A Proposal for Case Definitions and Outcome Measures in Studies of Infantile Spasms and West Syndrome: consensus Statement of the West Delphi Group. Epilepsia. 2004 [cited 2018 Aug 1];45:1416–1428. http://www.ncbi.nlm.nih.gov/pubmed/15509243
- Nabbout R, Belousova E, Benedik MP, et al. Epilepsy in tuberous sclerosis complex: findings from the TOSCA Study. Epilepsia Open. 2019 cited 2023 May 10;4:73–84. DOI:10.1002/epi4.12286
- Joinson C, O’Callaghan FJ, Osborne JP, et al. Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol Med. [cited 2019 Feb 28]. 2003;33:335–344. http://www.ncbi.nlm.nih.gov/pubmed/12622312
- Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet. [cited 2018 Jun 11]. 2004;364:1773–1778. http://www.ncbi.nlm.nih.gov/pubmed/15541450
- Curatolo P, Jóźwiak S, Nabbout R. Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations. Eur J Paediatr Neurol. [cited 2019 Feb 28] 2012;16:582–586. https://linkinghub.elsevier.com/retrieve/pii/S1090379812001237
- Krueger DA, Northrup H, Northrup H, et al. Tuberous Sclerosis Complex Surveillance and Management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol [Internet]. 2013 [cited 2019 Feb 28];49:255–265. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0887899413004918
- Tibussek D, Klepper J, Korinthenberg R, et al. Treatment of Infantile Spasms: report of the Interdisciplinary Guideline Committee Coordinated by the German-Speaking Society for Neuropediatrics. Neuropediatrics 2016 [cited 2017 Nov 7];47:139–150. DOI:10.1055/s-0036-1572411
- Curatolo P, Nabbout R, Lagae L, et al. Management of epilepsy associated with tuberous sclerosis complex: updated clinical recommendations. Eur J Paediatr Neurol Internet. [cited 2019 Feb 28] 2018;22(5):738–748. http://www.ncbi.nlm.nih.gov/pubmed/29880258
- Ramantani G, Bölsterli BK, Alber M, et al. Treatment of Infantile Spasm Syndrome: update from the Interdisciplinary Guideline Committee Coordinated by the German-Speaking Society of Neuropediatrics. Neuropediatrics 2022;53:389–401. DOI:10.1055/a-1909-2977
- Kotulska K, Kwiatkowski DJ, Curatolo P, et al. Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial. Ann Neurol. 2021;89(2):304–314. DOI:10.1002/ana.25956
- Pesaturo KA, Spooner LM, Belliveau P. Vigabatrin for infantile spasms. Pharmacotherapy. 2011. [[cited 2019 Mar 22]];31(3):298–311. http://doi.org/10.1592/phco.31.3.298.
- Ben-Menachem E. Mechanism of action of vigabatrin: correcting misperceptions. Acta Neurol Scand. 2011 [[cited 2019 Mar 22]];124:5–15. http://www.ncbi.nlm.nih.gov/pubmed/22061176
- Bialer M. Chemical properties of antiepileptic drugs (AEDs). Adv Drug Deliv Rev [Internet]. [cited 2019 Mar 22] 2012;64(10):887–895. https://linkinghub.elsevier.com/retrieve/pii/S0169409X11002869
- Gaily E. Vigabatrin monotherapy for infantile spasms. Expert Rev Neurother. [cited 2019 Mar 22] 2012;12:275–286. http://www.tandfonline.com/doi/full/10.1586/ern.12.3
- Zhang B, Mcdaniel SS, Rensing NR, et al. Vigabatrin Inhibits Seizures and mTOR Pathway Activation in a Mouse Model of Tuberous Sclerosis Complex. PLoS ONE. 2013 [cited 2023 May 14];8:57445. DOI:10.1371/journal.pone.0057445
- Heim MK, Gidal BE. Vigabatrin-associated retinal damage: potential biochemical mechanisms. Acta Neurol Scand. 2012. [cited 2019 Mar 22];126(4):219–228. http://doi.org/10.1111/j.1600-0404.2012.01684.x
- Pearl PL, Vezina LG, Saneto RP, et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia. 2009;50:184–194. http://www.ncbi.nlm.nih.gov/pubmed/18783433
- Wheless JW, Carmant L, Bebin M, et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia [Internet]. 2009 [cited 2019 Mar 22];50:195–205. Available from: 10.1111/j.1528-1167.2008.01896.x.
- Dracopoulos A, Widjaja E, Raybaud C, et al. Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms. Epilepsia [Internet]. 2010 [cited 2019 Mar 22];51(7):1297–1304. http://doi.org/10.1111/j.1528-1167.2010.02564.x
- O’Callaghan FJK, Edwards SW, Alber FD, et al. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol. [cited 2017 Nov 9] 2017;16(1):33–42. http://www.ncbi.nlm.nih.gov/pubmed/27838190
- Gronseth G, Cox J, Gloss D, et al. 2017 edition: clinical practice guideline process manual. Am Acad Neurol [Internet]. 2017 [cited 2023 May 16];1–76. https://www.aan.com/siteassets/home-page/policy-and-guidelines/guidelines/about-guidelines/17guidelineprocman_pg.pdf./
- Page MJ, Mckenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. [cited 2023 Feb 1]; Available from; doi: 10.1136/bmj.n71
- Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011 [cited 2017 Jun 19];343:d5928. http://www.bmj.com/content/343/bmj.d5928
- Chiron C, Dumas C, Jambaqué I, et al. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res. [cited 2019 Mar 22]. 1997;26:389–395. http://www.ncbi.nlm.nih.gov/pubmed/9095401
- Elterman RD, Shields WD, Mansfield KA, et al. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001;57:1416–1421. http://www.ncbi.nlm.nih.gov/pubmed/11673582
- Elterman RD, Shields WD, Bittman RM, et al. Vigabatrin for the treatment of infantile spasms: final report of a randomized trial. J Child Neurol. [cited 2019 Mar 22]. 2010;25:1340–1347. http://journals.sagepub.com/doi/10.1177/0883073810365103
- Chiron C, Dulac O, Beaumont D, et al. Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol 1991 [cited 2018 Jul 28];2:S52–9. http://www.ncbi.nlm.nih.gov/pubmed/1940125
- Hussain SA, Schmid E, Peters JM, et al. High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex. Epilepsy Res. 2018 [cited 2019 Mar 22];148:1–7. http://www.ncbi.nlm.nih.gov/pubmed/30296632
- Vigevano F, Cilio MR. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. Epilepsia. 1997 [[cited 2017 Nov 7]];38:1270–1274. http://www.ncbi.nlm.nih.gov/pubmed/9578521
- Grinspan ZM, Knupp KG, Patel AD, et al. Comparative Effectiveness of Initial Treatment for Infantile Spasms in a Contemporary US Cohort. Neurology. 2021;97:e1217–1228.
- Aicardi J, Mumford JP, Dumas C, et al. Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril is Investigator and Peer Review Groups. Epilepsia. 1996;37:638–642. http://www.ncbi.nlm.nih.gov/pubmed/8681895
- Camposano SE, Major P, Halpern E, et al. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. Epilepsia. [Internet]. 2008 [cited 2019 Mar 22];49:1186–1191. http://doi.org/10.1111/j.1528-1167.2008.01589.x
- Bombardieri R, Pinci M, Moavero R, et al. Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. Eur J Paediatr Neurol. 2010 [cited 2019 Mar 22];14:146–149. https://linkinghub.elsevier.com/retrieve/pii/S1090379809000567
- Hsieh DT, Jennesson MM, Thiele EA. Epileptic spasms in tuberous sclerosis complex. Epilepsy Res. [cited 2019 Mar 22] 2013;106:200–210. https://linkinghub.elsevier.com/retrieve/pii/S0920121113001435
- Yum M-S, Lee EH, Ko T-S. Vigabatrin and mental retardation in tuberous sclerosis: infantile spasms versus focal seizures. J Child Neurol. [cited 2019 Mar 22] 2013;28:308–313. http://journals.sagepub.com/doi/10.1177/0883073812446485
- Overwater IE, Bindels-de Heus K, Rietman AB, et al. Epilepsy in children with tuberous sclerosis complex: chance of remission and response to antiepileptic drugs. Epilepsia [Internet]. 2015 [cited 2019 Mar 22];56:1239–1245. http://doi.org/10.1111/epi.13050
- Wilbur C, Sanguansermsri C, Chable H, et al. Manifestations of Tuberous Sclerosis Complex: the Experience of a Provincial Clinic. Can J Neurol Sci 2017 [cited 2019 Mar 22];44:35–43. http://www.journals.cambridge.org/abstract_S0317167116003115
- van der Poest Clement EA, Sahin M, Peters JM, et al. Vigabatrin for Epileptic Spasms and Tonic Seizures in Tuberous Sclerosis Complex. J Child Neurol. [cited 2019 Mar 22] 2018;33:519–524. http://www.ncbi.nlm.nih.gov/pubmed/29687739
- Alrifai MT, Al-Rumayyan AR, Al-Tuwaijri WA, et al. The response patterns of infantile spasms to treatments in 156 patients Hormonal therapy with intravenous synthetic ACTH appears promising. Neurosciences. 2022;27:40–44.
- Buoni S, Zannolli R, Strambi M, et al. Combined treatment with vigabatrin and topiramate in West syndrome. J Child Neurol. [cited 2019 Mar 22]. 2004;19:385–386. http://www.ncbi.nlm.nih.gov/pubmed/15224711
- Policy & Guidelines [Internet]. Am. Acad. Neurol. 2019 [cited 2019 Mar 22]. Available from: https://www.aan.com/policy-and-guidelines/guidelines/
- Jeong A, Nakagawa JA, Wong M. Predictors of Drug-Resistant Epilepsy in Tuberous Sclerosis Complex. J Child Neurol. [cited 2019 Mar 22] 2017;32:1092–1098. http://www.ncbi.nlm.nih.gov/pubmed/29129154
- Perez J, Chiron C, Musial C, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia. 1999;40:1618–1626. http://www.ncbi.nlm.nih.gov/pubmed/10565591
- Patsalos PN. Drug Interactions with the Newer Antiepileptic Drugs (AEDs)—Part 2: pharmacokinetic and Pharmacodynamic Interactions Between AEDs and Drugs Used to Treat Non-Epilepsy Disorders. Clin Pharmacokinet. [cited 2015 May 6] 2013;52:1045–1061. http://www.ncbi.nlm.nih.gov/pubmed/23794036
- Riikonen R. Recent Advances in the Pharmacotherapy of Infantile Spasms. CNS Drugs. 2014 [[cited 2018 Aug 2]];28:279–290. http://www.ncbi.nlm.nih.gov/pubmed/24504827
- Singh R, Carson RV StatPearls [Internet]. 2023 [cited 2023 Apr 29]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK557579/
- Go CY, Mackay MT, Weiss SK, et al. Evidence-based guideline update: medical treatment of infantile spasms: report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2012 [cited 2017 Nov 7];78:1974–1980. http://www.ncbi.nlm.nih.gov/pubmed/22689735
- O’Callaghan FJK, Edwards SW, Alber FD, et al. Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial. Lancet Child Adolesc Heal. [cited 2023 Apr 30]. 2018;2:715–725. https://pubmed.ncbi.nlm.nih.gov/30236380/
- Augustine EF, Adams HR, Mink JW. Clinical Trials in Rare Disease: challenges and Opportunities. J Child Neurol. [cited 2023 Apr 29] 2013;28:1142. https://pmc/articles/PMC3964003/
- Hilgers RD, Roes K, Stallard N, et al. Directions for new developments on statistical design and analysis of small population group trials. Orphanet J Rare Dis. [cited 2023 Apr 29]. 2016;11:1–10. https://ojrd.biomedcentral.com/articles/10.1186/s13023-016-0464-5
- PreveNT - Preventing Epilepsy Using Vigabatrin in Infants with Tuberous Sclerosis Complex [Internet]. [cited 2019 Mar 22]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02849457?term=prevent+and+tsc&rank=1